Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Stopped Study population more infrequent than estimated. No study-related safety issues and no safety concerns were identified for the study.

Conditions

• Pancreatic Neoplasms
• Cholestasis

Interventions

• DRUG: nab-paclitaxel
• DRUG: Gemcitabine

Sponsor

Celgene